Promising signs for stem cell-based therapies for Parkinson’s in two new studies

Welcome to Lab Dish, a new First Opinion column on regenerative medicine from Paul Knoepfler.

I’m upbeat about cell therapy development for Parkinson’s disease, but it has been a marathon. Now two new clinical trial papers published Wednesday in Nature on stem cell-based therapies for Parkinson’s are another step forward.

However, they also highlight remaining challenges and dilemmas, including the optimal doses of cells, the extent of engraftment, and whether to use allogeneic or autologous cells.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In